influenza ha

Influenza HA (110-119) refers to a specific fragment (110-119) derived from the hemagglutinin protein of the influenza virus. This fragment has the ability to induce the proliferation of Treg cells.

Influenza HA (110-119) acetate is the 110-119 fragment of influenza virus hemagglutinin that can stimulate Treg cells proliferation[1][2].

Influenza HA (518-526) is an immunodominant epitope in H2d mice post flu virus infection.

Influenza HA (126-138) is a peptide derived from the hemagglutinin (HA) protein of the influenza virus, consisting of amino acids 126-138, and has the ability to induce apoptosis in both thymic and peripheral T-cells.

Influenza Hemagglutinin is an HLA-DRB 0101-restricted epitope from influenza hemagglutinin (307-319).

Influenza HA 126-138 acetate is a influenza virus hemagglutinin (HA) peptide acetate comprising amino acids 126-138. Influenza HA 126-138 acetate induces thymic and peripheral T-cell apoptosis.

Anti-Influenza HA Antibody (3E1) is an antibody. Its expression system is HEK293 cells, the clone number is 3E1, and the isotype control is IgG2, Kappa.

Anti-Influenza HA Antibody (CR6261) is an antibody. Its expression system is HEK293 cells, the clone number is CR6261.

Influenza HA (307-319) acetate is the 307-319 amino acid fragment of the influenza virus hemagglutinin (HA) protein, an HLA-DRB1 0101-restricted epitope polypeptide with the sequence PKYVKQNTLKLAT, which can be used for the study of influenza virus immunogenicity as well as for the development of vaccines and diagnostic reagents against influenza virus.

Anti-Influenza A H10 Hemagglutinin/HA Antibody (8B805) is a Mouse IgG1 monoclonal antibody targeting Influenza Influenza A H10 Hemagglutinin/HA.

CBS1117 is a virus entry inhibitor with an IC50 of 70 nM for influenza A virus, A/Puerto Rico/8/34 (H1N1). It interferes with the hemagglutinin (HA)-mediated fusion process.

MBX2329 is a specific inhibitor of HA-mediated viral entry that inhibits H1N1 virus strain high pathogenic avian influenza H5N1 virus strain.

JNJ4796 is an orally active fusion inhibitor of the influenza virus, inhibiting hemagglutinin (HA)-mediated fusion to neutralize the influenza A group 1 virus. JNJ4796 mimics the functionality of broadly neutralizing antibodies (bnAbs).

6,6′-Trehalose dioleate (6,6′-TDO) is a glycolipid extensively used for in vivo and in vitro mRNA delivery. This compound effectively encapsulates mRNA encoding hemagglutinin A (HA) from influenza A virus for use within lipid nanoparticles (LNPs), enhancing the secretion of Ifn-γ, Il-2, and Tnf-α from isolated murine spleen cells. When administered via intramuscular injection in mice, LNPs containing 6,6′-TDO predominantly accumulate in the liver and spleen. Unlike LNP formulations without 6,6′-TDO, those containing 6,6′-TDO do not reduce serum levels of blood urea nitrogen (BUN) or elevate levels of lactate dehydrogenase (LDH), troponin I, alanine aminotransferase (ALT), or aspartate aminotransferase (AST). Additionally, these LNPs enhance the serum titers of IgG1 and IgG2a antibodies in mice.

PAN endonuclease-IN-2 (compound T-31) is a PAN endonuclease inhibitor (IC50: 0.15 μM) and has antiviral properties with broad-spectrum anti-influenza activity. PAN, as the N-terminal PA subunit of the polymerase-RNA complex, possesses a cap-dependent endonuclease (CEN) active site, facilitating RNA cleavage and initiating the synthesis of new RNA molecules. PAN endonuclease-IN-2 targets both influenza HA and RdRp complexes, thereby disrupting viral entry into host cells and impeding viral replication.

MBX2546 is an Influenza A Virus Fusion Inhibitor. MBX2546 binds to HA and inhibits HA-mediated membrane fusion. Both binding and stabilization of HA by MBX2546 are required for the inhibition of viral infection. Mutations in MBX2546-resistant influenza A/

RO5487624 is an inhibitor of Influenza A HA-Mediated Fusion.

9(S),12(S),13(S)-TriHOME is a linoleic acid-derived oxylipin that has diverse biological activities.1,2,3,4It has been found in various plants and is produced in human eosinophils in a 15-lipoxygenase-dependent, soluble epoxide hydrolase-independent manner.1,59(S),12(S)13(S)-TriHOME inhibits antigen-induced β-hexosaminidase release from RBL-2H3 mast cells (IC50= 28.7 μg/ml).2It inhibits LPS-induced nitric oxide (NO) production in BV-2 microglia (IC50= 40.95 μM).3In vivo, 9(S),12(S),13(S)-TriHOME (1 g/animal) enhances the antiviral IgA and IgG antibody responses induced by a nasal influenza hemagglutinin (HA) vaccine by 5.2- and 2-fold, respectively, in mice.4 1.Hamberg, M., and Hamberg, G.Peroxygenase-catalyzed fatty acid epoxidation in cereal seeds: Sequential oxidation of linoleic acid into 9(S),12(S),13(S)-trihydroxy-10(E)-octadecenoic acidPlant Physiol.110(3)807-815(1996) 2.Hong, S.S., and Oh, J.S.Inhibitors of antigen-induced degranulation of RBL-2H3 cells isolated from wheat branJ. Korean Soc. Appl. Biol. Chem.5569-74(2012) 3.Kim, C.S., Kwon, O.W., Kim, S.Y., et al.Five new oxylipins from Chaenomeles sinensisLipids49(11)1151-1159(2014) 4.Shirahata, T., Sunazuka, T., Yoshida, K., et al.Total synthesis, elucidation of absolute stereochemistry, and adjuvant activity of trihydroxy fatty acidsTetrahedron62(40)9483-9496(2006) 5.Fuchs, D., Tang, X., Johnsson, A.-K., et al.Eosinophils synthesize trihydroxyoctadecenoic acids (TriHOMEs) via a 15-lipoxygenase dependent processBiochim. Biophys. Acta Mol. Cell Biol. Lipids1865(4)158611(2020)

CAY10766 is an antiviral compound.1It inhibits entry of influenza virus-like particles pseudotyped with hemagglutinin A (HA) from H5N1 influenza A virus into A549 cells (EC50= 0.24 μM). CAY10766 (1 μM) reduces H1N1 and H5N1 influenza A viral titers in infected MDCK cells. It also exhibits synergy with oseltamivir carboxylate in MDCK cells infected with the influenza A reporter PR8-NS1-Gluc virus.

Influenza virus-IN-5 (Compound 5f) is an inhibitor of influenza virus hemagglutinin (HA) with an EC50 of 1 nM against the A/H3N2 virus.

CBS1194 is a novel antiviral agent against influenza A virus (IAV), and is more specifically, a group 2 IAV fusion inhibitor. CBS1194 prevents membrane fusion of the virus through the inhibition of the conformational change of hemagglutinin (HA). CBS1194 causes steric hinderance that prevents the rearrangement of the HA that would normally be induced by low-pH, by fitting into the pocket by the fusion peptide.

LUN15104 is a novel hemagglutinin (HA) protein inhibitor, inhibiting entry and replication of diverse influenza viruses via the HA protein, showing potent antiviral activity against diverse H1N1, H5N1, and H3N2 influenza viruses encoding HA proteins from both groups 1 and 2. This product has no formal name. For the convenience of scientific communication, we named it by combining its InChi Key (3 letters from the first letter of each section) with the last 5 digit of its CAS#) according to MedKoo Chemical Nomenclature (https://www.medkoo.com/page/naming).

PROTAC Hemagglutinin Degrader-1 (Compound V3) is a potent degrader of influenza hemagglutinin (HA) with a median degradation concentration of 1.44 μM and broad-spectrum anti-influenza virus activity [1].

Influenza A virus-IN-8 (S5), a macrocyclic peptide, exhibits no cytotoxicity and acts as a potent inhibitor of Influenza A Virus (IAV), demonstrating significant protease stability, with IC50 values of 6.7 nM for H1 and 6.6 nM for H5 variants. It has a high affinity for H1 variants, binding to a conserved region in the HA stem with a dissociation constant (Kd) of 1.0 nM [1].